title: Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients.
abstract: African-Americans (AA) have higher acute rejection rates and poorer long-term graft survival rates when compared with non-AA. It is yet to be demonstrated that the type of induction therapy modifies outcomes in this 'high-risk' population. This retrospective analysis compares the efficacy of induction therapy [antilymphocyte antibodies (ALA) versus interleukin-2 receptor antagonists (IL-2RA)] in the AA population. Some 189 AAs were included. There was no difference in acute rejection at one year between the groups (ALA (12%) or IL-2RA (12%), P = 0.89). Type of induction therapy had no significant effect on death-censored (P = 0.61) or uncensored graft survival (P = 0.32). There was no difference between CMV or BK virus infections between the groups (P = 0.14 and 0.94 respectively). Type of induction therapy does not appear to affect acute rejection rates or long-term graft survival in low-risk AA kidney transplant recipients.
authors: Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC 29425, USA.
authors: James N
authors: JN
authors: Fleming
authors: David J
authors: DJ
authors: Taber
authors: Nicole A
authors: NA
authors: Weimert
authors: Maria F
authors: MF
authors: Egidi
authors: John
authors: J
authors: McGillicuddy
authors: Charles F
authors: CF
authors: Bratton
authors: Angello
authors: A
authors: Lin
authors: Kenneth D
authors: KD
authors: Chavin
authors: Prabhakar K
authors: PK
authors: Baliga
mesh_terms: D000328:Adult; D001741:Black or African American; D000961:Antilymphocyte Serum / Q000276:immunology*; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit